Physician profile
Ranjan Prakash Malhotra
NPI 1396743555
$809,088.53
in general payments reported to CMS, 2019-2025
41 companies · $196K in 2025
The $196K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $73K · 2021: $111K · 2022: $82K · 2023: $87K · 2024: $139K · 2025: $196K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $157K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Consulting Fee: $42K · Honoraria: $39K · Food and Beverage: $29K · Travel and Lodging: $23K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $156,508.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,745.00 |
| Consulting Fee | $41,850.65 |
| Honoraria | $39,225.00 |
| Food and Beverage | $28,547.97 |
| Travel and Lodging | $22,973.12 |
| Education | $105.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $190,967.54 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $111,162.30 | 2019-2022 | |
| Abbvie INC. | $93,538.99 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $79,973.73 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $46,677.12 | 2023-2025 | Vevye, Triesence, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46,639.92 | 2019-2021 | |
| Biotissue Holdings INC. | $36,450.14 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $31,777.18 | 2019-2025 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $29,130.44 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $27,036.13 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $26,832.81 | 2019-2023 | Flarex |
| Novartis Pharmaceuticals Corporation | $24,784.82 | 2019-2023 | |
| Oyster Point Pharma, INC. | $14,713.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $13,454.21 | 2019 | |
| Ocular Therapeutix, INC. | $8,544.81 | 2019-2024 | Dextenza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,035.36 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Clareon Panoptix Pro |
| Tearlab Corp | $3,819.99 | 2019-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Eyepoint US, INC. | $3,493.59 | 2019-2021 | |
| New World Medical,INC. | $3,387.70 | 2019-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Glaukos Corporation | $2,807.53 | 2020-2025 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $1,824.17 | 2019-2025 | Tecnis Iol, Tecnis Iol, Amo Phaco Needle |
| Thea Pharma INC. | $1,599.62 | 2022-2025 | Azasite, Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $1,436.98 | 2022-2025 | Lumera 700, Quatera 700, Visumax |
| Mallinckrodt Hospital Products INC. | $901.89 | 2022-2025 | Acthar |
| Carl Zeiss Meditec, INC. | $752.05 | 2019-2022 | |
| Rxsight INC | $714.71 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ivantis, INC | $561.88 | 2019-2021 | |
| Dompe US, INC. | $554.85 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $257.93 | 2024-2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $230.25 | 2023 | Tepezza |
| Ucb, INC. | $215.00 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $146.48 | 2022 | |
| Amgen INC. | $124.69 | 2024 | Tepezza |
| Topcon Healthcare Solutions, INC. | $117.48 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $107.34 | 2025 | Purified Cortrophin Gel |
| Coopervision INC. | $106.50 | 2025 | Misight Contact Lens |
| Carl Zeiss Meditec Production LLC | $69.03 | 2019 | |
| Leica Microsystems INC. | $61.00 | 2024 | Surgical Microscopes |
| Beaver-Visitec International, INC. | $60.00 | 2025 | |
| Omeros Corporation | $18.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,074.40 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjan Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.